Biogen Idec Sets New 1-Year High at $353.47 (BIIB)
Biogen Idec (NASDAQ:BIIB) shares reached a new 52-week high on Monday , Analyst Ratings Net reports. The company traded as high as $353.47 and last traded at $349.00, with a volume of 1,112,110 shares changing hands. The stock had previously closed at $347.11.
Several analysts have recently commented on the stock. Analysts at Leerink Swann raised their price target on shares of Biogen Idec from $322.00 to $351.00 in a research note on Thursday. They now have an “outperform” rating on the stock. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Biogen Idec in a research note on Tuesday, February 18th. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Biogen Idec in a research note on Friday, February 7th. Nine analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $303.13.
The stock has a 50-day moving average of $309.1 and a 200-day moving average of $262.6. The company has a market cap of $81.705 billion and a price-to-earnings ratio of 44.44.
Biogen Idec (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $2.34 earnings per share for the quarter, beating the analysts’ consensus estimate of $2.27 by $0.07. The company had revenue of $2.00 billion for the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter last year, the company posted $1.40 earnings per share. Biogen Idec’s revenue was up 38.6% compared to the same quarter last year. Analysts expect that Biogen Idec will post $11.35 EPS for the current fiscal year.
In other Biogen Idec news, EVP Steven Holtzman unloaded 1,222 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $327.90, for a total transaction of $400,693.80. Following the sale, the executive vice president now directly owns 9,412 shares of the company’s stock, valued at approximately $3,086,195. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Biogen Idec Inc (NASDAQ:BIIB) is a global biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.